Cipher Surgical

The company’s OpClear® device uses a patented technology to keep a laparoscope's lens clear of contaminants (condensation, blood, tissue, fluids etc.) during an operation, without removing the scope from the patient.

The proceeds of this fundraise are being used for working capital to support the completion and launch of OpClear in Europe and obtain FDA approval.

The company is led by Andrew Newell (MD) who has worked as a venture capitalist for over 23 years, specialising in intellectual property, most recently within the healthcare field.

www.ciphersurgical.com

We are delighted by the traction we received from VentureFounders network of high profile, sophisticated investors.

ANDREW NEWELL CEO OF CIPHER SURGICAL

KEY INVESTMENT HIGHLIGHTS

  • Product successfully validated through pre-clinical trials and surgeon endorsement

  • Sizeable industry estimated at £44 billion with no single versatile solution

  • Patents granted within US, Europe and Japan

  • Strong management team with significant track record